GlobalData: Leading medical robots used by the healthcare industry
The researchers looked specifically at death or non-fatal cardiopulmonary arrest (heart attack) during hospitalization.
The researchers learned that adults taking "first-generation" or "typical" antipsychotic medications (medicines first developed around the 1950s) were significantly more likely to experience death or cardiopulmonary arrest, compared to people who did not take those drugs. Taking "atypical" or "second-generation" antipsychotics (so named because they were developed later) raised the risk for death or cardiopulmonary arrest only for people aged 65 or older.
In the past, other studies have suggested that typical antipsychotic medications could cause sudden death, and that atypical antipsychotics could raise peoples' risks for falls, pneumonia and death. What's more, another large study also suggested that both types of antipsychotic medicines posed a risk for fatal heart attacks.
Despite these known risks, atypical antipsychotics are often prescribed for people in the hospital. One recent study of patients at Beth Israel Deaconess Medical Center in Boston found that antipsychotics were prescribed for nine percent of all adults who were hospitalized for non-psychiatric causes. Another large recent study found that using antipsychotics to prevent or treat delirium did not lower the risk for death, did not lessen the severity of delirium or shorten its duration, and did not shorten the time people spent in the intensive care unit (ICU) or their hospital length of stay.
"Delirium is common in older hospitalized patients and difficult to treat, but antipsychotic medications should be used with caution regardless of age," said the authors. Source:
American Geriatrics Society Journal reference:
Basciotta, M., et al. (2019) Antipsychotics and the Risk of Mortality or Cardiopulmonary Arrest in Hospitalized Adults. Journal of the American Geriatrics Society . doi.org/10.1111/jgs.16246 .
Also in Industry News
How to decide whether or not to start treatment for prostate cancer?
Analysis of the SARS-CoV-2 proteome via visual tools
$65m investment increases British Patient Capital’s exposure to life sciences and health technology